Aktuellt
SENASTE
Redeye provides its initial take on Surgical Science’s Q3 2023 report, which came in broadly below our estimates. We judge that notable positives from the report include EBITDA and EBIT margins coming in c3%-points higher than we anticipated. Notable negatives include anaemic sales growth, especially for Educational Products.
LÄS MER
